<DOC>
	<DOCNO>NCT02279654</DOCNO>
	<brief_summary>This registry prospective , non-interventional , post authorisation safety study patient diagnose Transfusion Dependent , IPSS low intermediate-1-Risk Myelodysplastic Syndrome ( MDS ) , associate single abnormality chromosome 5 [ del ( 5q ) ] . The purpose study collect additional data safety oral drug ( lenalidomide , Revlimid® ) may prescribe relieve anemia decrease need blood transfusion . However , also patient affect MDS del ( 5q ) receive treatment different lenalidomide include study , agree .</brief_summary>
	<brief_title>Non-interventional Study Lenalidomide Clinical Routine Treatment TD Patients With IPSS Low Int-1 MDS Isolated Del ( 5q )</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Lenalidomide</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Are ≥ 18 year old time signing Informed consent form ( ICF ) Are transfusion dependent history transfusion dependence ; purpose current Myelodysplastic syndrome ( MDS ) Postauthorization safety study ( PASS ) , transfusiondependence define require ≥2 RBC unit 8 week period prior date signature ICF ( due MDSrelated cause hemorrhage , trauma , acute cause ) Are active treatment lenalidomide ( Lenalidomide Cohort ) never expose lenalidomide time sign ICF ( Background Cohort ) Have confirm diagnosis IPSS low intermediate1risk MDS isolate del ( 5q ) ( morphological cytogenetic information ) diagnose 15 June 2007 ( date Revlimid first approve Europe ) later Refuse participate Myelodysplastic syndrome ( MDS ) Postauthorization safety study ( PASS ) , Are currently participate interventional therapeutic clinical trial MDS ( except erythropoiesisstimulating agent [ ESAs ] granulocyte colonystimulating growth factor ) Receive investigational agent time sign ICF Have previously treat lenalidomide longer active treatment lenalidomide time sign ICF</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Lenalidomide</keyword>
	<keyword>Revlimid</keyword>
	<keyword>Transfusion-dependent</keyword>
	<keyword>international Prognostic Scoring System ( IPSS ) low</keyword>
	<keyword>Intermediate-1-risk</keyword>
	<keyword>MDS</keyword>
	<keyword>Isolated del ( 5q )</keyword>
	<keyword>Prospective</keyword>
	<keyword>Non-interventional</keyword>
	<keyword>Post-authorization safety study ( PASS )</keyword>
	<keyword>Disease registry</keyword>
</DOC>